Category: Epidarex Portfolio News
Brighton, UK, April 5, 2017 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, has won funding from the Cystic Fibrosis Trust to identify new drug mechanisms for the treatment of cystic…
Hamburg, April 4, 2017 – Topas Therapeutics GmbH (“Topas”), a privately held biotech company pursuing a novel liver-based immune tolerance approach, today announced the election of Paul Sekhri as Chairman of the Board effective immediately. Paul Sekhri is currently CEO and President of the US…
Edinburgh, United Kingdom, February 27, 2017 – Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for the treatment of metabolic disease, including Type 2 Diabetes and non-alcoholic steatohepatitis (NASH),…
Baltimore, MD, February 21, 2017 – Harpoon Medical, Inc., a clinical stage medical device company focused on the development and commercialization of transcatheter beating heart mitral valve repair technology, announced today that the company has hired Laura Brenton to serve as Vice President of Clinical Affairs. …
Glasgow, Scotland, 30th January 2017: Mironid® Limited, a leader in cell signalling-directed drug discovery, is delighted to start the New Year by initiating a £606K programme to expand its repertoire of proprietary LoAc® molecules. The work will be 70% funded by the UK’s innovation agency,…
Aberdeen, United Kingdom, January 10, 2017 – SIRAKOSS Ltd., a UK-based medical device company developing innovative bone grafting solutions for the $3 billion global orthopaedic market, has announced that the United States Patent and Trademark Office (USPTO) has granted two patents for its bone graft…
Berlin, Germany, 09 January 2017 – Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3) million Series A funding round. Epidarex Capital led the round, and Evotec AG participated together with a consortium of investors…
Mironid’s ShoLo® and LoAc® programmes benefit from a close association with Dr George Muller as a key medicinal chemistry and experienced drug development advisor. George was an Outstanding Investigator and Senior Director of Chemistry with Celgene until his retirement in mid-2011. George has a deep…